c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, Rafael B., Francoz, Sarah, Santamaría, David, Cañamero, Marta, Dubus, Pierre, Charron, Jean, Baccarini, Manuela, Barbacid, Mariano·2011·Cancer Cell

DOI 10.1016/j.ccr.2011.04.002

Cited by (305)

Items 101–200 of 305

Tumor suppressor role of phospholipase Cε in Ras-triggered cancers
Marta Martins, Afshan McCarthy, Rhona W. Baxendale, Sabrina Guichard, Lorenza Magno, Nicoletta Kessaris, Mona A El-Bahrawy, Philipp Yu, Matilda Katan · 2014 · Proceedings of the National Academy of Sciences
The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
Wada, Makoto, Horinaka, Mano, Yamazaki, Toshikazu, Katoh, Norito, Sakai, Toshiyuki · 2014 · PLoS ONE
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
Thomas Yul Avery, Natalie Köhler, Robert Zeiser, Tilman Brummer, Dietrich Alexander Ruess · 2022 · Frontiers in Oncology
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Jackie L. Johnson, Smitha Pillai, Srikumar Chellappan · 2012 · Biochemistry Research International
SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
Isabel Boned del Río, Lucy C. Young, Sibel Sarı, Greg G. Jones, Benjamin Ringham-Terry, Nicole Hartig, Ewa Rejnowicz, Winnie Lei, Amandeep Bhamra, Silvia Šurinová et al. · 2019 · Proceedings of the National Academy of Sciences
In vivo gene manipulation reveals the impact of stress‐responsive MAPK pathways on tumor progression
Miki Kamiyama, Isao Naguro, Hidenori Ichijo · 2015 · Cancer Science
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan, Liang, Tu, Bo, Yao, Jun, Gong, Jing, Carugo, Alessandro, Bristow, Christopher A., Wang, Qiuyun, Zhu, Cihui, Dai, Bingbing, Kang, Ya'an et al. · 2021 · Cancer Research
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
María Romina Girotti, Grazia Saturno, Paul C. Lorigan, Richard Marais · 2014 · Molecular Oncology
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Matthias Drosten, Mariano Barbacid · 2021 · Molecular Oncology
Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
Hajime Yurugi, Fédérico Marini, C Weber, Kerstin A. David, Qian Zhao, Harald Binder, Laurent Désaubry, Krishnaraj Rajalingam · 2017 · Oncogene
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Avinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, Frances Shanahan, Benjamin Haley, Lilian Phu, Erik Verschueren, Trent B. Hinkle, David Kan, Ehud Segal et al. · 2022 · Cell Reports
Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Gisele Nishiguchi, Alice C. Rico, Huw R. Tanner, Robert J. Aversa, Benjamin R. Taft, Sharadha Subramanian, L Setti, Matthew T. Burger, Lifeng Wan, Victoriano Tamez et al. · 2017 · Journal of Medicinal Chemistry
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward · 2023 · Clinical Cancer Research
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Marie‐Julie Nokin, Élodie Darbo, Camille Travert, Benjamin Drogat, Aurélie Lacouture, Sonia San José, Nuria E. Cabrera-Benítez, Béatrice Turcq, Valérie Prouzet‐Mauleon, Mattia Falcone et al. · 2020 · JCI Insight
Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations
Krishna R. Kalari, David Rossell, Brian M. Necela, Yan W. Asmann, Asha Nair, Saurabh Baheti, Jennifer M. Kachergus, Curtis S. Younkin, Tiffany R. Baker, Jennifer M. Carr et al. · 2012 · Frontiers in Oncology
ERK2 but not ERK1 mediates HGF-induced motility in non small cell lung carcinoma cell lines
Simone Radtke, Mina Milanovic, Carine Rossé, Manu De Rycker, Sylvie Lachmann, Andrew P. Hibbert, Stéphanie Kermorgant, Peter J. Parker · 2013 · Journal of Cell Science
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Wenlin Shao, Yuji M. Mishina, Yunjiang Feng, Giordano Caponigro, Vesselina G. Cooke, Stacy Rivera, Yingyun Wang, Fang Shen, Joshua M. Korn, Lesley A. Mathews Griner et al. · 2018 · Cancer Research
Efforts to Develop KRAS Inhibitors
Holderfield, Matthew · 2018 · Cold Spring Harbor Perspectives in Medicine
Signaling Pathways in Hepatocellular Carcinoma
Daniela Sia, Augusto Villanueva · 2011 · Oncology
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Penglei Wang, Kyle Vaughn Laster, Xuechao Jia, Zigang Dong, Kangdong Liu · 2023 · Molecular Cancer
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
Melody Riaud, Jennifer Maxwell, Isabel Soria‐Bretones, Matthew Dankner, Meredith Li, April A. N. Rose · 2024 · Nature reviews. Cancer
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
Xi Yuan, Zhiyu Tang, Rong Du, Zhan Yao, Shing‐Hu Cheung, Xinwen Zhang, Jing Wei, Yuan Zhao, Yunguang Du, Ye Liu et al. · 2020 · Molecular Oncology
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
Rafael Rosell, Jordi Codony‐Servat, Jessica González, Mariacarmela Santarpía, Anisha S Jain, Chandan Shivamallu, Yu Wang, Ana A. Giménez-Capitán, Miguel Ángel Molina‐Vila, Jonas A. Nilsson et al. · 2023 · Critical Reviews in Oncology/Hematology
Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma
Zehua Zhu, Hadrien G. Golay, David Allen Barbie · 2014 · Pharmacogenomics
The presence of Merkel cell polyomavirus is associated with deregulated expression of BRAF and Bcl‐2 genes in non‐small cell lung cancer
Ismini Lasithiotaki, Katerina M. Antoniou, Stavros Derdas, E. Sarchianaki, Emmanouil K. Symvoulakis, Anna Psaraki, Demetrios A. Spandidos, E. Stathopoulos, Nikolaos M. Siafakas, George Sourvinos · 2013 · International Journal of Cancer
Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance
Zhikun Liu, Meng Wang, Heng‐Shan Wang, Lei Fang, Shaohua Gou · 2019 · Journal of Medicinal Chemistry
PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, Shon, Trejo, Christy L., McMahon, Martin · 2015 · Cancer Research
Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
Kiruthikah Thillai, Hoyin Lam, Debashis Sarker, Claire M. Wells · 2016 · Oncotarget
The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation
Taiane Schneider, Arturo Martinez-Martinez, Monica Cubillos‐Rojas, Ramón Bartrons, Francesc Ventura, José Luís Rosa · 2018 · Oncotarget
Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors
Eslam M.H. Ali, Mohammed S. Abdel‐Maksoud, Usama M. Ammar, Karim I. Mersal, Kyung Ho Yoo, Park Jooryeong, Chang‐Hyun Oh · 2020 · Bioorganic Chemistry
Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets
Matthias Drosten, Carmen E. Guerra, Mariano Barbacid · 2017 · Cold Spring Harbor Perspectives in Medicine
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Anais Del Curatolo, Fabiana Conciatori, Ursula Cesta Incani, Chiara Bazzichetto, Italia Falcone, Vincenzo Corbo, Sabrina L. D’Agosto, Adriana Eramo, Giovanni Sette, Isabella Sperduti et al. · 2018 · Journal of Experimental & Clinical Cancer Research
Genetically engineered mouse models of PI3K signaling in breast cancer
Sjoerd Klarenbeek, Martine H. van Miltenburg, Jos Jonkers · 2013 · Molecular Oncology
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis
Ines Jerić, Gabriele Maurer, Anna Lina Cavallo, Josipa Raguz, Enrico Desideri, Bartosz Tarkowski, Matthias Parrini, Irmgard Fischer, Kurt Zatloukal, Manuela Baccarini · 2016 · Nature Communications
Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression
Michelle Cicchini, Elizabeth L. Buza, Kyra M. Sagal, A. Andrea Gudiel, Amy C. Durham, David M. Feldser · 2017 · Cell Reports
Dysregulated Tgfbr2/ERK-Smad4/SOX2 Signaling Promotes Lung Squamous Cell Carcinoma Formation
Yanxiao Wang, Xiaohong Tan, Yuling Tang, Chong Zhang, Jiaqian Xu, Jian Hua Zhou, Xuan Cheng, Ning Hou, Wenjia Liu, Guan Yang et al. · 2019 · Cancer Research
RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression
Manuel Sanclemente, Patricia Nieto, Sara García‐Alonso, Fernando Fernández-García, Laura Esteban-Burgos, Carmen E. Guerra, Matthias Drosten, Eduardo J. Caleiras, Jorge Luis Martinez-Torrecuadrada, David Santamarı́a et al. · 2021 · Cancer Cell
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
Andrew M. Waters, Tala O. Khatib, Bjoern Papke, Craig M. Goodwin, G. Aaron Hobbs, J. Nathaniel Diehl, Runying Y. Yang, A. Cole Edwards, Katherine H. Walsh, Rita Sulahian et al. · 2021 · Cell Reports
Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making
Donna M. Dambach, Dinah Misner, Mathew Brock, Aaron M. Fullerton, William R. Proctor, Jonathan M. Maher, Dong Hun Lee, Kevin A. Ford, Dolores Diaz · 2015 · Chemical Research in Toxicology
In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma
Chiara Ambrogio, Mariano Barbacid, David Santamarı́a · 2016 · Oncogene
Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma
Nicolas Dumaz · 2011 · Small GTPases
KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
Nastaran Karimi, Seyed Javad Moghaddam · 2023 · Cells
NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity
Kelley Ingram, Shiela C. Samson, Rediet Zewdu, Rebecca G. Zitnay, Eric L. Snyder, Michelle C. Mendoza · 2021 · Oncogene
Mouse Models of Human Cancer
Barbara C. Böck, Ulrike Stein, Clemens A. Schmitt, Hellmut G. Augustin · 2014 · Cancer Research
Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
Hiroshi Kotani, Yuta Adachi, Hidenori Kitai, Shuta Tomida, Hideaki Bando, Anthony C. Faber, Takayuki Yoshino, Dominic Chih‐Cheng Voon, Seiji Yano, Hiromichi Ebi · 2018 · Oncogene
Functional and structural insights into RAS effector proteins
Alessandro Mauro Mozzarelli, Dhirendra K. Simanshu, Pau Castel · 2024 · Molecular Cell
miRNA‐214 is related to invasiveness of human non‐small cell lung cancer and directly regulates alpha protein kinase 2 expression
Hogir Salim, Alexandros Arvanitis, Luigi De Petris, Lena Kanter, Petra Hååg, Ana Zovko, Deniz Mahmut Özata, Weng‐Onn Lui, Lovisa Lundholm, Boris Zhivotovsky et al. · 2013 · Genes Chromosomes and Cancer
Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer
Tijana Borovski, Thomas Tiede Vellinga, Jamila Laoukili, Evan E. Santo, Szabolcs Fátrai, Susanne van Schelven, André Verheem, Dieuwke Louise Marvin, Inge Ubink, Inne H.M. Borel Rinkes et al. · 2016 · Gut
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis
F Kern, Eszter Doma, Christian Rupp, Théodora Niault, Manuela Baccarini · 2012 · Oncogene
Blimp1 Activation by AP-1 in Human Lung Cancer Cells Promotes a Migratory Phenotype and Is Inhibited by the Lysyl Oxidase Propeptide
Ziyang Yu, Seiichi Sato, Philip C. Trackman, Kathrin H. Kirsch, Gail E. Sonenshein · 2012 · PLoS ONE
Inhibition of SHP2 as an approach to block RAS-driven cancers
Yu‐Ting Chou, Trever Grant Bivona · 2022 · Advances in cancer research
SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells
Theodore Vougiouklakis, Kenbun Sone, Vassiliki Saloura, Hyun‐Soo Cho, Takehiro Suzuki, Naoshi Dohmae, Houda Alachkar, Yusuke Nakamura, Ryuji Hamamoto · 2015 · Oncotarget
In Vitro and In Vivo Antitumor Activity of a Novel Semisynthetic Derivative of Cucurbitacin B
Izabella Thaís Silva, Annelise Carvalho, Karen Luise Lang, Sabine Eva Dudek, Dörthe Masemann, Fernando Durán, Miguel S. B. Caro, Ulf Rüdiger Rapp, Viktor Wixler, Eloir Paulo Schenkel et al. · 2015 · PLoS ONE
Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches
Martine H. van Miltenburg, Jos Jonkers · 2012 · Current Opinion in Genetics & Development
Extracellular Signal-Regulated Kinases: One Pathway, Multiple Fates
Xavier Deschênes‐Simard, Mohan K. Malleshaiah, Gerardo Ferbeyre · 2023 · Cancers
Ras isoform-specific expression, chromatin accessibility, and signaling
Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, Hyunbum Jang · 2021 · Biophysical Reviews
RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status
Coralie Dorard, Claire Madry, Olivier Buhard, Stefanie Toifl, Sebastian Didusch, Toky Ratovomanana, Quentin Letourneur, Helmut Dolznig, Mathew J. Garnett, Alex Duval et al. · 2023 · Oncogene
Systems biology approaches to develop innovative strategies for lung cancer therapy
Kristina Viktorsson, Rolf Lewensohn, Boris Zhivotovsky · 2014 · Cell Death and Disease
c-Raf in KRas Mutant Cancers: A Moving Target
Frank P. McCormick · 2018 · Cancer Cell
Isoform-Specific Roles of ERK1 and ERK2 in Arteriogenesis
Nicolas Ricard, Jiasheng Zhang, Zhen W. Zhuang, Michael Simons · 2019 · Cells
Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells
Mohamad Assi, Younès Achouri, Axelle E. Loriot, Nicolas Dauguet, Hajar Dahou, Jonathan Baldan, Maxime Libert, Jean S. Fain, Carmen E. Guerra, Luc Bouwens et al. · 2021 · Cancer Research
Ablation of BRaf Impairs Neuronal Differentiation in the Postnatal Hippocampus and Cerebellum
Verena Pfeiffer, Rudolf Götz, Chaomei Xiang, Guadelupe Camarero, Attila Braun, Yina Zhang, Robert Blum, Helmut Heinsen, Bernhard Nieswandt, Ulf Rüdiger Rapp · 2013 · PLoS ONE
H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences
Matthias Drosten, Lucía Simón-Carrasco, Isabel Hernández-Porras, Carmen G. Lechuga, María Teresa Blasco, Harrys K.C. Jacob, Salvatore Fabbiano, Nicoletta Potenza, Xosé R. Bustelo, Carmen E. Guerra et al. · 2016 · Cancer Research
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation
Dong Man Jang, Kayla Boxer, Byung Hak Ha, Emre Tkacik, Talya S. Levitz, Shaun D. Rawson, Rebecca J. Metivier, Anna M. Schmoker, Hyesung Jeon, Michael J. Eck · 2025 · Nature Communications
AGO2 promotes tumor progression in KRAS-driven mouse models of non–small cell lung cancer
Jean Ching-Yi Tien, Seema Chugh, Andrew E. Goodrum, Yunhui Cheng, Rahul Mannan, Yuping Zhang, Lisha Wang, Vijaya L. Dommeti, Xiaoming Wang, Alice Xu et al. · 2021 · Proceedings of the National Academy of Sciences
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Cen Liu, Danyang Ye, Hongliu Yang, Xu Chen, Zhijun Su, Xia Li, Mei Ding, Yonggang Liu · 2023 · MedComm
Role of Prohibitins in Aging and Therapeutic Potential Against Age-Related Diseases
Misa Belser, David W. Walker · 2021 · Frontiers in Genetics
Advances in the Genetics and Biology of Pancreatic Cancer
Andrew J. Aguirre, Eric Andrew Collisson · 2017 · The Cancer Journal
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas
Laura Esteban-Burgos, Haiyun Wang, Patricia Nieto, Jie Zheng, Carmen Blanco‐Aparicio, Carmen Varela, Gonzalo Goméz-López, Fernando Fernández-García, Manuel Sanclemente, Carmen E. Guerra et al. · 2020 · Proceedings of the National Academy of Sciences
Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
Natalia Garcia, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman et al. · 2021 · Molecular Cancer Therapeutics
Mechanisms of aneuploidy induction by RAS and RAF oncogenes.
Tamihiro Kamata, Catrin A. Pritchard · 2011 · Europe PMC (PubMed Central)
Requirement for epithelial p38α in KRAS-driven lung tumor progression
Jessica Vitos‐Faleato, Sebastián Real, Nuria Gutierrez-Prat, Alberto Villanueva, Elisabet Llonch, Matthias Drosten, Mariano Barbacid, Ángel R. Nebreda · 2020 · Proceedings of the National Academy of Sciences
Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK–ERK/AP-1 pathway
Santosh Chauhan, Douglas D. Boyd · 2011 · Nucleic Acids Research
Selective CRAF Inhibition Elicits Transactivation
Charles W. Morgan, Ian L. Dale, Andrew P. Thomas, James Hunt, Jason W. Chin · 2021 · Journal of the American Chemical Society
Mitogen-activated protein kinase pathway in osteosarcoma
Kiyong Na, Youn Wha Kim, Yong-Koo Park · 2012 · Pathology
Activation of MEK1/2‐ERK1/2 signaling during NNK‐induced lung carcinogenesis in female A/J mice
Keiko Yamakawa, Masanao Yokohira, Yuko Nakano, Sosuke Kishi, Shohei Kanie, Katsumi Imaida · 2016 · Cancer Medicine
BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer
Fabiana Conciatori, Chiara Bazzichetto, Carla Azzurra Amoreo, Isabella Sperduti, Sara Donzelli, Maria Grazia Diodoro, Simonetta Buglioni, Italia Falcone, Senji Shirasawa, Giovanni Blandino et al. · 2020 · Communications Biology
Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer
J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan‐Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, Channing J. Der · 2022 · Advances in cancer research
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, Feng Bi · 2024 · Acta Pharmaceutica Sinica B
The Stress-Response MAP Kinase Signaling in Cardiac Arrhythmias
Xun Ai, Jiajie Yan, Elena Carrillo, Wenmao Ding · 2016 · Reviews of physiology, biochemistry and pharmacology
Practical Use of Advanced Mouse Models for Lung Cancer
Roghaiyeh Safari, Ralph Leo Johan Meuwissen · 2015 · Methods in molecular biology
ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers
Juliane Mooz, Kristina Riegel, Hari PS, Anguraj Sadanandam, Fédérico Marini, Matthias Klein, Ulrike Werner, Wilfried Roth, Annett Wilken‐Schmitz, Irmgard Tegeder et al. · 2022 · Science Advances
Metastasis-Associated Protein 2 Represses NF-κB to Reduce Lung Tumor Growth and Inflammation
Nefertiti Adly El-Nikhely, Annika Karger, Poonam Sarode, Indrabahadur Singh, Andreas Weigert, Astrid Wietelmann, Thorsten Stiewe, Reinhard Dammann, Ludger Fink, Friedrich Grimminger et al. · 2020 · Cancer Research
Loss of RhoA Exacerbates, Rather Than Dampens, Oncogenic K-Ras Induced Lung Adenoma Formation in Mice
Inuk Zandvakili, Ashley Kuenzi Davis, Guodong Hu, Yi Zheng · 2015 · PLoS ONE
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.
Jie Liao, Sung Hee Hwang, Haonan Li, Jun‐Yan Liu, Bruce D. Hammock, Guang Yu Yang · 2016 · PubMed
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
Yasmine N. White, Aditi Bagchi, Jessica Van Ziffle, Anagha Inguva Sheth, Gideon E. Bollag, Chao Zhang, Heidi Carias, David S. Dickens, Mignon L. Loh, Kevin Shannon et al. · 2016 · Nature Communications
Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells
Byong Hoon Yoo, Iman Aftab Khan, Ananda Koomson, Pramod S. Gowda, Takehiko Sasazuki, Senji Shirasawa, Shashi Ashok Gujar, Kirill V. Rosen · 2017 · Autophagy
Conditional Expression of Oncogenic C-RAF in Mouse Pulmonary Epithelial Cells Reveals Differential Tumorigenesis and Induction of Autophagy Leading to Tumor Regression
Fatih Ceteci, Jiajia Xu, Semra Ceteci, Emanuele Zanucco, Chitra Thakur, Ulf Rüdiger Rapp · 2011 · Neoplasia
Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis
Ka‐Wing Cheng, Chi Chun Wong, Ninche Alston, Gerardo Guillermo Mackenzie, Liqun Huang, Nengtai Ouyang, Gang Xie ., Timothy Scott Wiedmann, Basil Rigas · 2013 · Molecular Cancer Therapeutics
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma
Haitang Yang, Yanyun Gao, Duo Xu, Ke Xu, Shun‐Qing Liang, Yang Zhang, Amina Scherz, Sean R. R. Hall, Stefan Forster, Sabina Berezowska et al. · 2023 · Cell Death Discovery
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, Sandra Vietti Michelina, Edoardo Garbo, Silvia Novello, David Santamarı́a, Chiara Ambrogio · 2024 · Molecular Oncology
Overview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer
Clare Sheridan, Julian Downward · 2015 · Current Protocols in Pharmacology
Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor
Grinu Mathew, Abdul Hannan, Kristina Hertzler-Schaefer, Fen Wang, Gen‐Sheng Feng, Jian Zhong, Jean J. Zhao, Julian Downward, Xin Zhang · 2016 · Proceedings of the National Academy of Sciences
KRASG12C inhibitor: combing for combination
Atanu Chakraborty · 2020 · Biochemical Society Transactions
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
Özge Tatlı, Gizem Dinler Doğanay · 2021 · Molecules
Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy
María Fernanda Montenegro, Román Martí-Díaz, Ana Navarro, Jorge Tolivia, Luís Sánchez‐del‐Campo, Juan Cabezas‐Herrera, José Neptuno Rodríguez‐López · 2023 · Cell Death and Disease
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome
Alberto Diaz-Jimenez, Maria Ramos, Barbara Helm, Sara Chocarro, Dario L. Frey, Shubham Agrawal, Kálmán Somogyi, Ursula Klingmüller, Junyan Lu, Rocı́o Sotillo · 2024 · Drug Resistance Updates
New RAF kinase inhibitors in cancer therapy
Juan Martín-Liberal, James Larkin · 2014 · Expert Opinion on Pharmacotherapy
Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets
Matthias Drosten, Mariano Barbacid · 2015 · Journal of Molecular Medicine
Inhibition of mutant KrasG12D -initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t -CUPM
Jie Liao, Sung Hee Hwang, Haonan Li, Yihe Yang, Jun Yang, Aaron T. Wecksler, Jun‐Yan Liu, Bruce D. Hammock, Guang‐Yu Yang · 2015 · Cancer Letters